Non-Hallucinogenic Psychedelics

Psychedelics have shown promise in treating various mental health issues, including PTSD and depression, but they’ve often faced notable challenges. Side effects like nausea, cardiovascular risks, and the potential for "bad trips" have raised concerns among both clinicians and patients. As...

Canadian drug development company Diamond Therapeutics Inc. announced it has successfully completed its Phase 1 clinical study on low-dose psilocybin and shared the trial’s most relevant results.  The Toronto-based company is focused on sub-perceptual, non-hallucinogenic treatments that...